ES2031882T3 - Metodo y composicion para profilaxis y tratamiento de infecciones viricas. - Google Patents

Metodo y composicion para profilaxis y tratamiento de infecciones viricas.

Info

Publication number
ES2031882T3
ES2031882T3 ES198787300589T ES87300589T ES2031882T3 ES 2031882 T3 ES2031882 T3 ES 2031882T3 ES 198787300589 T ES198787300589 T ES 198787300589T ES 87300589 T ES87300589 T ES 87300589T ES 2031882 T3 ES2031882 T3 ES 2031882T3
Authority
ES
Spain
Prior art keywords
treatment
viral infections
prophylaxis
composition
aids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787300589T
Other languages
English (en)
Inventor
Grace Hing-Wah Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/822,099 external-priority patent/US4828830A/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2031882T3 publication Critical patent/ES2031882T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LAS INFECCIONES VIRICAS SE PUEDEN PREVENIR O TRATAR POR ADMINISTRACION DE UN FACTOR DE NECROSIS DE TUMORES, Y PREFERIBLEMENTE POR INFUSION CONTINUA DEL INDICADO FACTOR DE NECROSIS DE TUMORES E INTERFERON. EL METODO TIENE APLICABILIDAD PARTICULAR EN EL TRATAMIENTO DEL SIDA Y ARC (COMPLEJO RELACIONADO CON EL SIDA).
ES198787300589T 1986-01-24 1987-01-23 Metodo y composicion para profilaxis y tratamiento de infecciones viricas. Expired - Lifetime ES2031882T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/822,099 US4828830A (en) 1986-01-24 1986-01-24 Method and composition for prophylaxis and treatment of viral infections
US89253186A 1986-07-31 1986-07-31

Publications (1)

Publication Number Publication Date
ES2031882T3 true ES2031882T3 (es) 1993-01-01

Family

ID=27124616

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787300589T Expired - Lifetime ES2031882T3 (es) 1986-01-24 1987-01-23 Metodo y composicion para profilaxis y tratamiento de infecciones viricas.

Country Status (11)

Country Link
EP (1) EP0235906B1 (es)
JP (1) JP2510181B2 (es)
CN (1) CN1023295C (es)
AU (1) AU598225B2 (es)
CA (1) CA1296252C (es)
DE (1) DE3765137D1 (es)
DK (1) DK169234B1 (es)
ES (1) ES2031882T3 (es)
GR (1) GR3001091T3 (es)
IL (1) IL81367A0 (es)
NZ (1) NZ219027A (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1290249C (en) * 1986-04-09 1991-10-08 Cetus Corporation COMBINATION THERAPY USING INTERLEUKIN-2 AND/OR INTERFERON-.beta. AND TUMOR NECROSIS FACTOR
US4879111A (en) * 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
AU633525B2 (en) * 1988-11-15 1993-02-04 Sanwa Kagaku Kenkyusho Co., Ltd. Enhancers for biosynthetic interferon and compositions containing them as well as preparations for making aids asymptomatic and curing aids and compositions therefor
US5200176A (en) * 1989-10-06 1993-04-06 Genentech, Inc. Method for protection of ischemic tissues using tumor nerosis factor
US5370870A (en) * 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
EP0421023B1 (de) * 1989-10-06 1995-03-15 MUCOS EMULSIONSGESELLSCHAFT m.b.H. Katabolische Enzyme zur Induktion des Tumornekrose-Faktors (TNF)
EP0554381B2 (en) * 1990-10-25 2000-04-26 Genentech, Inc. Use of protective agents against reactive oxygen species
ES2214551T3 (es) * 1995-11-02 2004-09-16 Schering Corporation Terapia de infusion continua de citocinas a baja dosis.
EP1415655A4 (en) * 2001-07-19 2005-12-21 Akira Hayashi IMMUNOTHERAPY FOR PEOPLE
CN105031620A (zh) * 2015-07-14 2015-11-11 天津瑞普生物技术股份有限公司 一种针对鸡胚的禽呼肠孤病毒抑制方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2513124B1 (fr) * 1981-07-21 1989-11-17 Hayashibara Biochem Lab Production et applications du facteur de lyse des cellules-cibles
IL71954A0 (en) * 1983-06-01 1984-09-30 Genentech Inc Gamma interferon-lymphotoxin synergism
CA1265444A (en) * 1983-06-27 1990-02-06 Lloyd J. Old Effect of human tumor necrosis factor and human interferon on human cancer cells and methods
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
GR851626B (es) * 1984-07-05 1985-11-26 Genentech Inc
JP2557053B2 (ja) * 1984-12-21 1996-11-27 バイオジェン インコーポレイテッド 腫瘍壊死因子の精製、製造および使用法
JPS6287525A (ja) * 1985-10-15 1987-04-22 Kanegafuchi Chem Ind Co Ltd 新規リンホトキシン含有抗腫瘍剤
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
PT85076B (pt) * 1986-06-16 1990-07-31 Genentech Inc Metodo para o tratamento de doencas infecciosas pela administracao de factor de necrose tumoral-alfa

Also Published As

Publication number Publication date
EP0235906B1 (en) 1990-09-26
IL81367A0 (en) 1987-08-31
CA1296252C (en) 1992-02-25
AU6796287A (en) 1987-07-30
CN87100480A (zh) 1987-11-11
AU598225B2 (en) 1990-06-21
GR3001091T3 (en) 1992-04-17
DK169234B1 (da) 1994-09-19
NZ219027A (en) 1989-09-27
JPS62215535A (ja) 1987-09-22
JP2510181B2 (ja) 1996-06-26
CN1023295C (zh) 1993-12-29
EP0235906A1 (en) 1987-09-09
DK37187A (da) 1987-07-25
DE3765137D1 (de) 1990-10-31
DK37187D0 (da) 1987-01-23

Similar Documents

Publication Publication Date Title
DE3880766D1 (de) Konjugate von interferon alpha mit immunglobulinen.
OA08724A (fr) Treatment of human viral infections by dsRNA combined with viral inhibitors.
FI943805A (fi) Substituoituja adeniinijohdannaisten käyttö multippeliskleroosin hoitoon
ES8606289A1 (es) Un procedimiento para la preparacion de piridazinaminas.
ES2125251T3 (es) Inhibidores de la proteasa del vih.
ATE76294T1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
DK441786A (da) Nucleosider, der kan anvendes terapeutisk
ES540645A0 (es) Aparato para el tratamiento del plasma.
ES2031882T3 (es) Metodo y composicion para profilaxis y tratamiento de infecciones viricas.
ES2155834T3 (es) Procedimiento de tratamiento de lesiones o de disminuciones celulares.
SE9101815L (sv) Behandling av sjukdom foerbunden med hiv-infektioner
EP0325129A3 (en) Disubstituted pyridines
DK0643973T3 (da) Anvendelse af humant interferon-beta til fremstilling af farmaceutiske præparater til behandling af kronisk myeloid leukæmi
ATE57097T1 (de) Mischung von interferon und cyclaradin.
ATE383161T1 (de) Kombination von product r mit einem antiviralen mittel in der behandlung von hiv infektionen
DE3861494D1 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren.
ES2052579T3 (es) Empleo de interferon alfa humano recombinante para la fabricacion de un medicamento para tratar el virus del sida.
ES8801625A1 (es) Procedimiento para preparar disulfuros heterociclicos
ES2066897T3 (es) 5,11-dihidro-6h-pirido(2,3-b)(1,4)benzodiazepin-6-onas y -tionas y su uso en la prevencion o el tratamiento del sida.
ES2072431T3 (es) D-acido aspartico beta-hidroxamato para el tratamiento de infecciones virales y de tumores.
ES2084821T3 (es) Composicion para estabilizar el plasma sanguineo en curso de pasteurizado.
ES2058555T3 (es) Medicamento para el tratamiento intralesional del carcinoma de celulas escamosas, con alfa-interferon humano recombinante.
DE69222636T2 (de) Anti-hiv protein, tap-29, aus trichosanthes, seine kodierende dna und therapeutischen anwendungen
DE3485282D1 (de) Zusammensetzung zur behandlung von boesartigen tumoren insbesondere bei tieren.
MX9400210A (es) Tratamiento de infecciones virales.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 235906

Country of ref document: ES